Targeted therapy of AML
Using next-generation sequencing to identify biomarkers in CML
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Novel technologies to detect minimal residual disease (MRD)
Todd E. Druley
Can we cure 50% of all multiple myeloma patients in the next five years?